<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03398369</url>
  </required_header>
  <id_info>
    <org_study_id>UVAMRICRTTRIAL</org_study_id>
    <nct_id>NCT03398369</nct_id>
  </id_info>
  <brief_title>Mechanistic Clinical Trial of Advanced Imaging for CRT</brief_title>
  <official_title>Advanced Imaging and Inflammatory Markers to Define Mechanisms of Response to CRT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a mechanistic clinical trial with randomization to guidance for the CRT procedure
      using cardiac magnetic resonance (CMR) and computed tomography angiography (CTA) versus a
      standard procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At baseline, patients will have CMR, CTA, echocardiography, blood testing, and
      cardiopulmonary exercise testing. They will also complete a heart failure questionnaire. In
      patients randomized to CMR guidance for the CRT procedure, LV lead placement will be guided
      by the MRI information related to scar, activation and anatomy. Patients will have follow-up
      assessments at 6 and 12 months. There will also be clinical follow-up for survival free of
      appropriate ICD therapies over 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2018</start_date>
  <completion_date type="Anticipated">January 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular end-systolic volume (LVESV) improvement</measure>
    <time_frame>One Year</time_frame>
    <description>Change in LVESV with cardiac resynchronization therapy (CRT)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Heart Failure, Systolic</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CMR-Guided CRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard CRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CMR/CTA Guidance for CRT</intervention_name>
    <description>The intervention is the use of CMR and CTA to determine the optimal pacing site in the left ventricle for cardiac resynchronization therapy (CRT) and guide left ventricular lead placement.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Chronic systolic HF

          2. LVEF 35% or less

          3. Guideline-based class I or II indication for CRT

        Exclusion Criteria:

          1. Inability to provide informed consent

          2. Pregnancy

          3. Presence of metal embedded in the body due to prior accident or injury, as documented
             by skull films or other imaging

          4. Cerebral aneurysm clips

          5. Cochlear implants

          6. Other metallic implants known to be contraindications to CMR (does not include
             pacemakers and ICDs)

          7. Severe claustrophobia

          8. Acute kidney injury

          9. Acute renal failure or chronic kidney disease with GFR &lt; 45 cc/min/1.73m2

         10. Liver transplant

         11. Gadolinium allergy

         12. &gt;10% premature ventricular contraction (PVC) burden; and 13) estimated &gt;10% atrial
             fibrillation (AF) burden based on available clinical data.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth C Bilchick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kenneth C Bilchick, MD</last_name>
    <phone>4349242465</phone>
    <email>bilchick@virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hollis Phillips, BA</last_name>
    <phone>434-243-0046</phone>
    <email>hp9r@hscmail.mcc.virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Hoover</last_name>
      <phone>434-243-4861</phone>
      <email>jrh5r@hscmail.mcc.virginia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 7, 2018</study_first_submitted>
  <study_first_submitted_qc>January 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2018</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Kenneth Bilchick, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

